DNA

[Alex Smith]

I'm glad that this one finally showed up on Cramer's radar - I've been riding this one since May and it's been good all the way. The have a ton of products in the pipline and their current group seems very good.

[Mike Johnson]

Would you add more at this price or wait for a pullback.

[Alex Smith]

well the target price set by s&p (which i normaly dont trust) was $93 as of may, 24, 2005 it was however considered over valued at just under $80/share. They also rate it as a strong buy. I personnaly bought DNA and AMD yesterday, i think both those stocks will do better than s&p projected.

[scott kreitz]

DNA reported non-GAAP EPS of $0.30 per share with strength coming from a number of line items including Herceptin, Avastin, Xolair and royalties. I think reimbursement for Herceptin and Avastin ahead of
formal approvals will drive upward revisions to 2005 and 2006 consensus forecasts, although I remain cautious on DNA's valuation.